443 related articles for article (PubMed ID: 24081976)
1. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
3. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
5. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
9. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
10. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
15. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
16. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
[TBL] [Abstract][Full Text] [Related]
17. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Kubovcakova L; Lundberg P; Grisouard J; Hao-Shen H; Romanet V; Andraos R; Murakami M; Dirnhofer S; Wagner KU; Radimerski T; Skoda RC
Blood; 2013 Feb; 121(7):1188-99. PubMed ID: 23264594
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]